GlassScriptPhysician profile
Jennifer Joses
NPI 1275588717
$2,118.16
in general payments reported to CMS, 2019-2025
25 companies · $367 in 2025
The $367 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $483 · 2022: $547 · 2023: $447 · 2024: $273 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,087.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $289.63 | 2021-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $201.49 | 2022 | |
| Novo Nordisk INC | $176.99 | 2021-2025 | Rybelsus, Ozempic |
| Biohaven Pharmaceuticals, INC. | $143.10 | 2021 | |
| Lilly USA, LLC | $128.86 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $121.00 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $119.42 | 2023-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.22 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $115.13 | 2022-2024 | Quviviq |
| Astellas Pharma US INC | $96.82 | 2023-2024 | Veozah |
| Braintree Laboratories, INC. | $94.77 | 2022-2025 | Sutab, Suflave |
| Pfizer INC. | $68.05 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.25 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.49 | 2023-2024 | Xifaxan |
| Mylan Specialty L.P. | $54.66 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $53.30 | 2021-2022 | |
| Abbvie INC. | $44.04 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $37.61 | 2021-2024 | Airsupra |
| Antares Pharma, INC. | $33.79 | 2024-2025 | Xyosted |
| Nevro Corp. | $20.48 | 2022 | |
| Corcept Therapeutics | $17.41 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $17.24 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.56 | 2022 | |
| Organon LLC | $15.69 | 2022 | |
| Sunovion Pharmaceuticals INC. | $15.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Joses listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.